低俗怪谈
US Publisher: What if COVID Outbreak is Part of the Pentagon's Biowarfare Plan?_我的网站

A | Pyongyang's assumptions with regard to Washington's potential role in the COVID-19 pandemic apparently stem from a bombshell report by professors Jeffrey D Sachs and Neil L Harrison, published in May 2022 by peer-reviewed multidisciplinary scientific journal, The Proceedings of the National Academy of Sciences of the United States of America (PNAS).,"Prof Jeffrey Sachs of Columbia University had spent two years as chairman of the Lancet Commission on COVID and recently published a major paper in the prestigious PNAS journal arguing that the virus was very likely artificial, also calling for an independent inquiry into its possible American origins, but virtually all western media outlets ignored his dramatic reversal," says Ron Unz, an American technology entrepreneur, political activist, writer and the publisher of the Unz Review.,On 27 May, Sachs and Harrison released an op-ed for Project Syndicate, arguing that US authorities suppressed inquiries into the role US scientific research institutions may have played in creating the conditions of the COVID pandemic. "Yet if the coronavirus did indeed come from a lab, US culpability is almost certain," the professors insisted, calling for independent probes "not only into the outbreak in Wuhan, China, but also into the relevant US scientific research, international outreach, and technology licensing in the lead-up to the pandemic.",According to Sachs and Harrison, "the full story of the outbreak could involve America’s role in researching coronaviruses and in sharing its biotechnology with others around the world." The professors pointed out that "US scientists who work with SARS-like coronaviruses regularly create and test dangerous novel variants" to develop drugs and vaccines against them. These experiments, also known as "gain-of-function" research, have been conducted for decades prompting concerns that one day they could lead to an accidental outbreak or end up in the wrong hands, the scholars highlighted.,"In June, [Sachs] went even further in his public statements at a Spanish think-tank, describing the COVID virus as probably having an American origin," notes Unz. "In my opinion, Prof Sachs is merely stating what many senior figures in the West quietly believe or suspect but have been unwilling to mention publicly.",Situation in UkraineUS Has Helped Support 46 Biological Labs in Ukraine Over Last Two Decades, Pentagon Says9 June, 17:19 GMT,An Accidental Leak or a Warfare Tool?,America's experiments with viruses and dangerous pathogens have triggered concerns in Russia and China over the past few years. On 13 May 2020, Russia's Minister of Foreign Affairs Sergei Lavrov drew attention to a "dense network" of US biolabs located "along the perimeter of the Russian Federation and near Chinese borders".,Earlier this year, Beijing urged Washington to disclose the information about the activities of at least 360 biolabs in the world, presumably run by the US.,Since 2001, Russia, China, and many other countries have advocated the creation of a verification mechanism within the framework of the Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on their Destruction to ensure biosafety across the world. Nonetheless, the US was "about the only country" which has categorically opposed this proposal for roughly 20 years, Lavrov revealed in 2020.,"Over the past 70 years, America has invested an estimated $100Bln in developing the world's largest and longest-standing biowarfare program," says Unz.,Situation in UkraineWhat's Behind Washington's Denial of Biowarfare Weapons Programme in Ukraine?12 March, 15:50 GMT,The American publisher suggested that the US could be responsible for the COVID outbreak long before Sachs and Harrison did. Furthermore, Unz does not rule out that the pathogen was used as a deliberate biowarfare tool against China and, possibly, Iran by "elements of [the US] national security establishment, though without the direct knowledge or authorization of President Donald Trump.",There are a lot of unknowns about the mysterious pandemic which is believed to have come from the Huanan Seafood Market in Wuhan, China. For instance, neither a COVID-19 "patient zero" nor a "guilty bat" have been found, which means that SARS-CoV-2 may actually have been circulating among humans some time before the late 2019 Wuhan outbreak, according to CBS News.,In April 2020, ABC News broke the story that a special medical intelligence unit within the US Defense Intelligence Agency (DIA) in the second week of November 2019 produced a classified report warning about an "out-of-control disease epidemic" in the Wuhan area of China. It urged the US to protect its forces in Asia. Although a Pentagon spokesman officially denied the existence of that November report, Israel's broadcaster Channel 12 said the US had also shared the document in question with NATO and Israeli Defense Force (IDF).,It appears suspicious, according to Unz, that the DIA rushed to dub the mysterious disease an "epidemic" at a time when just a couple of dozen individuals were infected in Wuhan.,"It therefore appears that elements of the Defense Intelligence Agency were aware of the deadly viral outbreak in Wuhan more than a month before any officials in the Chinese government itself," Unz points out. "Furthermore, the New York Times and CNN have also promoted a major new research study just published in Science that found the first Wuhan infection probably occurred on 18 November 2019. This was after the secret DIA report had already been produced, but the American media has completely ignored the implications of this striking discrepancy.",Yet another strange coincidence was Donald Trump's appointment of Robert Kadlec as the top official for dealing with biological threats in 2017, the American writer says. Since the Nineties, Kadlec had been one of America’s leading biowarfare advocates.,"From January to August 2019, Kadlec’s department ran the 'Crimson Contagion' simulation exercise, involving the hypothetical outbreak of a dangerous respiratory viral disease in China, which eventually spreads to the United States, with the participants focusing on the necessary measures to control it in this country," Unz says, adding that before that China had suffered two inexplicable viral epidemics which hit its poultry and pork industry in 2018 and 2019, respectively.,Situation in UkraineUkraine Labs: Bioweapons Can be Used as Tool in US Low-Level War Against Russia, ex-DoD Analyst Says15 April, 12:51 GMT,History of Pentagon's Bio-warfare,Although the Pentagon's alleged responsibility for the COVID outbreak has yet to be examined and backed by solid evidence, one must admit that Washington is no novice where biological warfare is concerened.,The US was accused of using germ weapons against Korea during the Korean War (1950-1953) and China based on the testimony of at least 38 US military pilots.,In August 2021, Xinhua quoted witnesses and historians describing how the Pentagon used germ bombs in civilian areas in China and Korea to spread dozens of species of poisonous insects and germs.,And Havana leveled accusations against the Pentagon over the dengue epidemic in Cuba that contaminated 345,000 people in 1981 and an artificial outbreak of African swine fever (ASF) that led to the slaughter of 500,000 animals and inflicted considerable economic damage on the island nation in 1971. The US Department of Defense denied the allegations.,"Over the years highly regarded and fully mainstream American journalists and academics have published books and articles documenting America's extensive use of biowarfare during the Korean War and later as anti-food supply attacks against Cuba, East Germany, and other countries," notes Unz.,Recently, Russia's Ministry of Defense has revisited cases pertaining to the US history of biological warfare, while examining a trove of highly sensitive documents shedding light on the Pentagon's experiments with highly contagious pathogens in Ukraine. According to the MoD, the Pentagon's Defense Threat Reduction Agency (DTRA) division ran a network of biological labs in Ukraine with the aim of inflicting damage on Russia's people and economy.,"I'm certainly aware of the Russian Ministry of Defense public claims regarding the Pentagon's involvement in Ukrainian biolabs, and the preparation of possible biowarfare attacks against Russia," says Unz. "I don't have any special knowledge of this issue, but the apparent public admission by [Undersecretary of State] Victoria Nuland at a US Senate hearing convinced me that there was a high likelihood that these Russian accusations were correct.",Unz argues that "American military plans for biowarfare attacks against Russia dramatically increase the likelihood that similar measures had been prepared against China and Iran, and perhaps actually carried out by rogue elements of the Trump Administration." Although US secretive biological programs and the Pentagon's overseas biowarfare labs have been triggering further suspicions, the topic still remains largely neglected and suppressed by western mainstream media.。
原标题:拜登签行政命令,美国要推动生物技术进步!专家:中国CXO企业优势得天独厚9月13日,CXO(医药外包) 概念股走低。

B | 截至当日收盘,药明康德(603259.SH)、凯莱英(002821.SZ)跌停,康龙化成(300759.SZ)跌13.95%,博腾股份(300363.SZ)、九洲药业(603456.SH)、泰格医药(300347.SZ)跌超7%。美国当地时间9月12日,美国总统拜登签署了一项行政命令,以启动一项国家生物技术(Biotechnology)和生物制造(Biomanufacturing)倡议,涉及提高美国国内生物制造能力、扩大生物产品的市场机会等多个方面。此举旨在推动美国生物制造的进步。CXO是指药品从研发、临床试验、生产到上市过程中的一系列外包活动,产业链上下游包括CRO、CDMO/CMO、CSO,分别服务于医疗行业的研发外包、生产外包、销售外包三个环节。

C | 2021年以来,国内CXO行业迎来高速发展期,持续拓展海外市场。图片来源:图虫网9月13日,时代周报记者致电多家CXO企业。

D | 凯莱英方面表示,“公司在美国主要为小分子化药方面的合作,没有生物制药方面的业务。”博腾股份方面亦表示,在美国的业务以小分子为主,该项政策刚宣布,还没有具体举措,对公司业务尚未有实质性影响。泰格医药回应称,从目前公开消息来看,主要针对的是临床前CRO业务,对泰格医药目前业务没有影响,公司不涉及CDMO和生物医药业务。CIC灼识咨询合伙人王文华向时代周报记者解释,美国旨在鼓励本土生物制药产业发展,在细则出台之前对国内CXO企业的业绩影响尚不明朗。判断CXO行业发展趋势更侧重于基本面,此次政策影响偏向短期,对长期市场成长影响不大。王文华解释,国内CXO企业在生物制药的外包服务方面的优势得天独厚。其一,国内CXO企业的人力成本较低,且有充足的化学、药学等科研人员储备;其二,中国是全球最大的原料药生产国;其三,中国庞大的人口基数与充足的患者病例资源,国内CXO在临床阶段可针对各类细分疾病做到快速大量入组,加快新药研发进度。王文华还指出,国内CXO企业是国外生物制药企业的理想合作对象。近年,国内CXO企业在手订单飞速增长、海外市场份额持续提升。

E | “国内CXO企业长期会经历持续稳定的市场空间拓展。” 王文华说。去年以来,国内CXO行业业绩增长强劲。2022年上半年,主要CXO公司的营收、净利均呈现稳定增长趋势。

F | 与此同时,多家CXO主要收入也多来自国外市场。西南证券研报数据显示,在CXO板块的16家代表性企业中,2022年上半年合计收入426亿元,上涨73.2%;归母净利润约118.4亿元,涨86.6%;扣非归母净利润约95.9亿元,涨104.5%。药明康德是CXO板块龙头,目前市值2260.22亿元。

G | 药明康德通过全球32个营运基地和分支机构,为来自全球超5850家客户提供服务。2022年年中报显示,报告期内,药明康德实现营收177.56亿元,同比上涨68.52%;扣非净利润38.5亿元,同比上涨81%。其中,药明康德来自美国客户收入为119.09亿元人民币,同比增长104%,占总营收67.07%。9月13日上午,药明康德方面回应称,目前,公司业务和运营一切正常。

H | 2022年上半年,康龙化成营业收入46.35亿元,同比上涨41.06%。

I | 随着国际化战略的推进,公司在英国和美国共有11个运营实体,超过1300名员工。2022年上半年,海外子公司营业收入占公司营业收入的12.14%。同期,博腾股份营收39.14亿元,同比上涨211.67%。2022年中报显示,公司于2017年收购的J-STAR,已在美国拥有2个研发厂地,能够承接临床早期原料药CRO及制剂服务。2022年上半年,J-STAR实现营业收入1.31亿元,同比增长22%。返回搜狐,查看更多责任编辑:
。

J |
Current article:http://x1q.senchuoshaozaodidia.shop/vgw/zvtp4hj.html
Published on:01:50:42